Market Closed -
Hong Kong S.E.
04:09:05 2024-06-07 am EDT
|
5-day change
|
1st Jan Change
|
0.34
HKD
|
0.00%
|
|
0.00%
|
-65.66%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,069
|
918.1
|
382
|
134
|
-
|
-
|
Enterprise Value (EV)
1 |
2,376
|
610.3
|
386.5
|
134
|
134
|
134
|
P/E ratio
|
-0.63
x
|
-1.88
x
|
-1.03
x
|
-0.53
x
|
-0.41
x
|
-0.47
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
98.5
x
|
11.6
x
|
3.71
x
|
1.03
x
|
0.89
x
|
0.45
x
|
EV / Revenue
|
98.5
x
|
11.6
x
|
3.71
x
|
1.03
x
|
0.89
x
|
0.45
x
|
EV / EBITDA
|
-4.8
x
|
-2.11
x
|
-1.08
x
|
-0.81
x
|
-0.7
x
|
-1.25
x
|
EV / FCF
|
-5,183,168
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
1.02
x
|
2.95
x
|
-9.75
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
424,192
|
424,292
|
424,562
|
424,838
|
-
|
-
|
Reference price
2 |
8.880
|
2.450
|
0.9900
|
0.3400
|
0.3400
|
0.3400
|
Announcement Date
|
3/22/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
31.16
|
78.97
|
102.9
|
130
|
150
|
299.7
|
EBITDA
1 |
-
|
-639.4
|
-436
|
-353.8
|
-166.1
|
-191.5
|
-107.5
|
EBIT
1 |
-
|
-655.1
|
-476.6
|
-369.9
|
-192.2
|
-222.6
|
-136.9
|
Operating Margin
|
-
|
-2,102.46%
|
-603.52%
|
-359.57%
|
-147.83%
|
-148.42%
|
-45.69%
|
Earnings before Tax (EBT)
1 |
-
|
-1,077
|
-483.5
|
-378.8
|
-250.5
|
-324.1
|
-283.9
|
Net income
1 |
-846
|
-1,077
|
-483.5
|
-378.8
|
-250.5
|
-324.1
|
-283.9
|
Net margin
|
-
|
-3,456.26%
|
-612.21%
|
-368.26%
|
-192.67%
|
-216.03%
|
-94.73%
|
EPS
2 |
-15.11
|
-14.04
|
-1.302
|
-0.9638
|
-0.6380
|
-0.8260
|
-0.7230
|
Free Cash Flow
|
-
|
-592.2
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-1,900.31%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/30/21
|
3/22/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
4.44
|
-
|
-
|
-
|
Net Cash position
|
-
|
694
|
308
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.0125
x
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-592
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-155%
|
-96.5%
|
-282%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-146%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
739.4
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
8.710
|
0.8300
|
-0.1000
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
8.5
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
27.28%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/30/21
|
3/22/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
0.34
HKD Average target price
12.3
HKD Spread / Average Target +3,517.65% Consensus |
1st Jan change
|
Capi.
|
---|
| -65.66% | 18.49M | | +18.81% | 81.33B | | +14.11% | 9.14B | | -15.14% | 4.89B | | +46.88% | 4.61B | | +15.70% | 4.36B | | +7.51% | 2.26B | | -27.88% | 2.15B | | +15.73% | 2.1B | | -43.02% | 1.78B |
Specialty & Advanced Pharmaceuticals
|